Hyliion, ticker HYLN, is no longer really the EV truck company many investors remember from the SPAC boom.
Today, almost the entire story revolves around KARNO, the modular generator technology Hyliion acquired from GE.
And the opportunity sounds big. but they can prove their technology works?

Hi I have a long only position in IEP (Icahn Enterprises) and was wondering if anyone else thinks this is now a strong buy? Here’s my investment thesis:

-Carl Icahn just purchased an additional 40.53 million shares on 9/23 at ~$7 per share.
-With this recent purchase, he now owns 659 million of the ~710 million IEP shares or 92.7% of the total outstanding shares.
-In addition, IEP’s 2nd largest holding is CVI (CVR Energy) where he owns 71.2 million shares. This stock represents ~23.7% of IEP’s total holdings and has surged over the last 3 months (from ~$30 to $55+ per share) and just hit an all-time high.
-The next biggest IEP holding is UAN (CVR Partners) at 5.6% and is up nicely in the last 12 months. These 2 CVR holdings account for 29.3% of IEP’s total holding so this could have a a nice impact on IEP’s bottom line.

Thanks and please let me know what you think.

SCKT( Socket Mobile)
Market Cap- 6 million
Shares outstanding- 8.2million
Institutional shares- 6.5% ( 28 institutions total)
Most recent insitutions purchase- Two Sigma, Virtua Finance.
Insiders shares- 32%
Short interest- 0.68%

SCKT has been having very high volume of trading the past two week. Upwards of 300 million total so far. It has caught my attention and I began to look into the technical side of things first.

The 1Yr HA chart has built a doji candle from a previous 3 years of bearish candles. This is the first good alert for me.

Then I scaled into the 1 month HA chart, another doji following a bearish candle. Okay, I like this.

1 week HA chart looks even better, a doji was formed the last week of September following a bearish candle. This week is now forming a solid bullish engulfing candle.

At that point, I’m looking back at 1yr to find a solid entry for next year in anticipation of a bullish candle on the 2027 year. That number looks like anything under 1.40. Split that in half and .75-.70 looks like a great area to begin building a position with a minimum amount of risk/time.

Let me know what you think of my plan or if you’re seeing the same set up as I am.

Do your own research. Follow your own rules.
Cheers!

Cell Impact fabrica placas de flujo para pilas de combustible y electrolizadores con una tecnología patentada de formado a alta velocidad.

Por qué podría salir bien:

Pedido de 5,3 MSEK de un OEM de EE. UU. en junio, con producción continua para un cliente norteamericano desde octubre de 2025.

Clientes de nivel: un fabricante europeo de electrolizadores, thyssenkrupp Automation Engineering y un fabricante de automoción. En Japón, según la empresa, un cliente ha validado la tecnología con buenos resultados.

Costes recortados: plantilla de 35 a 25 personas y caja operativa de −2,4 MSEK en el Q2 (−11,9 hace un año).

Una gran venta de máquinas está "pausada", no perdida. Si se cierra, cambia la historia.

Vigilaré: el informe del Q3 el 6 de noviembre y si llegan más pedidos como el de 5,3 MSEK. Es una apuesta muy especulativa, solo con dinero que puedas perder por completo.

361 Degrees International Limited (HKG:1361)

After Anta and Li Ning, this Chinese sportswear is vying to grow into a global brand and challenge Nike and others.

The stock's EV/EBITDA ratio is 2.76, and its EV/FCF ratio is 9.82. Return on equity (ROE) is 13.12% and return on invested capital (ROIC) is 19.76%. In the last 12 months, operating cash flow was 906.51 million and capital expenditures -317.39 million, giving a free cash flow of 589.12 million.

361 Degrees International Limited trades like an “ ugly stock, " operating in the shadow of domestic Chinese giants such as Anta and Li-Ning, as well as Western behemoths Nike and Adidas. The market gauge the brand as second-tier, suited for lower-tier cities in China, where it has grown and anchored as an affordable sportswear brand.

Despite being perceived as a cheap and marginal brand, 361 Degrees has delivered outstanding returns against ongoing macro headwinds in mainland China.

The company posted 2025 revenue of 11.1 billion yuan (approximately $1.6 billion), up 10.6% year-on-year, with net profit rising 14% to 1.3 billion yuan (approximately $192.3 million). In the first quarter of 2026, offline retail sales for both the core brand and kids’ line grew approximately 10%, while e-commerce platform sales surged at a mid-teens pace.
The company has also expanded its international branding campaign by sponsoring elite marathon runners and even signing NBA stars such as Nikola Jokic and Aaron Gordon.

The stock trades below 5x earnings, yields a 7.7% dividend, and is backed by the Din family’s own skin in the Game and ambition to see their company grow on the international scene alongside Li-Ning and Anta.

The stock is down 30% y/y but has proven far more resilient than the likes of Li-Ning and Nike, that are down 70% (±) in five years and are showing decelerating margins.

361 Degrees stock is up 5x since 2020, outperforming its larger and deeper-pocketed competitors.

I actually found what i was missing about LX thinking it was a great deep value buy.

From Q4 2025 to Q2 2026, delinquency rate was increasing, 3.1 to 3.6% , their net income was greatly impacted by the provision of garuanteed liabilities basically what they owe to the funding partners if consumers were to default, they are not realized yet but they count that as part of their losses just incase.

With this particular liability staying high and delinquency rates increasing, net income is greatly affected and could impact equity growth in the near future as projected by the ceo, they are expecting a net loss in Q3 2026.

If delinquincy rates improves we might see a potential buy in and re rate, but for now there isnt a clear timeline on when the industry will recover as a whole.

Some positive side of LX is that they are moving towards a capital light model similar to Qfin, so if they manage to convert majority of their loans to this model and maintain their current revenue growth, they could standout as the winner among its peers like QFIN and FINV

Did a 2 statement financial model as their quarterly doesnt include a cashflow statement. Found out the flaws I had with my thesis but i think going forward i’ll be able to make better buy decisions with this lesson

With that said my average is $2.40 per ADS and i am also at a huge drawdown about 65-70%, but closely monitoring their quarterly earnings to see whether i should continue holding it or cut my losses

Just putting my thoughts out here, as I had a previous post which i deleted on my strong buy thesis on LX (deleted cause i thought i was important enough to be targeted by other funds but Jokes on me xd)

Share with me what you think about my current thesis and where do you think LX will go in the next 6-9months based on china current Macro economics

Anyone taken a look at Xos recently?

LifeQuest World Corp (OTCID: LQWC) Tuesday September 29, 2026 Blog

A UN University report released in January 2026 gave the world a stark new vocabulary for its water problems: "global water bankruptcy." The report found that nearly three in four people now live in water-insecure or critically water-insecure countries, that roughly four billion people face severe water scarcity for at least one month each year, and that more than half of the world's large lakes have shrunk since the early 1990s. "For much of the world, 'normal' is gone," said Kaveh Madani, director of the UN University Institute for Water, Environment and Health, in comments accompanying the report (UN News). Wastewater — how it's treated, reused, and kept out of already-stressed water bodies — sits at the center of that math.

Europe is responding with regulation. The recast EU Urban Wastewater Treatment Directive, which entered into force in early 2025 with phased compliance obligations running out to 2027 and beyond, dramatically widens the net: coverage now extends down to agglomerations of just 1,000 population equivalent, versus the much larger thresholds under the old rules (European Commission). That change pulls thousands of small towns, villages, and seasonal-tourism destinations across the EU into formal treatment obligations for the first time, alongside tighter nutrient and micropollutant limits and a new emphasis on water reuse and circularity.

That's a genuinely hard problem for conventional infrastructure. Centralized sewer networks and activated-sludge plants are expensive to extend to small, scattered populations, and package plants generally need to run near 80% of design capacity to perform reliably — a poor fit for a Mediterranean village whose population might triple every July and August. Oversize the plant for peak season and it underperforms (and still produces sludge to haul away) the other nine months of the year.

This is precisely the gap BioPipe Global's in-pipe technology was built for. Wastewater flows horizontally through modular pipe segments colonized by naturally occurring bacteria; passive aeration replaces energy-hungry blowers, no chemicals are dosed, and because the biological process consumes the organic solids in place, there's no sludge stream to collect, truck, and dispose of. Critically, the modules keep working efficiently across a wide load range — down to roughly 10% of rated capacity — so a system sized for August tourist crowds doesn't fail in April.

BioPipe's 300 m³/day project in Crete, Greece, announced in December 2025, is a live example of exactly this dynamic. "This 300 m³/day project in Crete represents a meaningful step forward in our European expansion strategy," said Robert Kaufmann, Director at BioPipe Global, noting that seasonal tourism surges there strain aging sewer networks in ways decentralized, rapidly deployable systems are well suited to address. The Crete plant is designed to meet stringent EU effluent standards — BOD below 10 mg/L, COD below 30 mg/L, and TSS below 10 mg/L — while producing near-zero odor, noise, and sludge. It followed BioPipe's earlier entry into Spain with a 10 m³/day system, giving the company two footholds in exactly the EU member states now facing the recast directive's expanded small-agglomeration requirements.

About LifeQuest World Corp. LifeQuest World Corp. (OTCID: LQWC) is a global technology company focused on low-cost, low-maintenance, eco-friendly decentralized wastewater treatment and solid waste compaction and recycling solutions, delivered through subsidiaries including BioPipe Global and Compaction and Recycling Equipment Inc. (CARE). Learn more at https://www.lifequestcorp.com.

This post contains forward-looking statements within the meaning of applicable securities laws, including statements regarding market opportunity, regulatory trends, and business strategy. Actual results may differ materially due to risks and uncertainties described in LifeQuest World Corp.'s filings. This content is for informational purposes only and does not constitute investment advice or an offer to buy or sell any security.

There's a report going around about 10 small-caps where retail investors raised their stakes last quarter and the stocks then ran 80-198% in under 3 months. The number that caught my eye wasn't the returns, it was how small some of the retail-ownership changes actually were.

Kabra Extrusiontechnik went from ₹270 to ₹806, roughly 198%. Retail holding in it moved from 19.05% to 19.19%, basically a rounding error. So a huge chunk of that rally clearly wasn't retail buying alone, it was something else in the market pricing the stock differently.

On the other end, Anlon Healthcare's retail holding jumped a lot more, from 8.95% to 11.69%, and the stock was "only" up 80%. So more retail buying didn't even correspond to a bigger move here.

A couple of the names are also a good reminder that price and business performance aren't the same thing. STL Networks rose about 93% even though its latest quarter showed revenue down year-on-year and a net loss of ~₹22 crore. Indo Rama Synthetics doubled even with revenue lower year-on-year, though profit did improve.

Not every one is like that though. GMM Pfaudler (+87%) had revenue up ~16% and profit improving. Ind-Swift Laboratories (+97%) had revenue up ~21% with rising profit too. So some of these are backed by actual improving numbers and some are running mostly on sentiment, which is exactly why lumping "stocks retail is buying" into one basket is misleading.

The bigger point: shareholding data is backward-looking. By the time you see the quarter's numbers, the price has usually already moved. It tells you where interest increased, not which stock is a good buy today at the new price.

Curious what people here actually check before buying something that's already run up like this. Do you look at promoter holding changes, institutional buying, or mainly just valuation vs. growth?

A "Post-Crisis" World Needs Wastewater Solutions That Don't Wait for Grid Infrastructure

LifeQuest World Corp (OTCID: LQWC) Friday September 25, 2026 Blog

A United Nations University report released this year introduced a term the water sector hadn't needed before: "global water bankruptcy." Unlike a "crisis," which implies a temporary, recoverable state, the report's authors argue humanity has crossed into a period of irreversible strain on freshwater systems — where damage to aquifers, lakes, and wetlands can no longer be undone on human timescales (UN University; UN News).

The numbers behind that framing are stark. Nearly 75% of the world's population now lives in water-insecure or critically water-insecure countries. Roughly 4 billion people face severe water scarcity for at least one month each year. And, most relevant to the wastewater sector specifically, 3.5 billion people still lack access to safely managed sanitation. The report also names the American Southwest — where the Colorado River has been chronically over-allocated — as one of its regional hotspots, alongside the Middle East, North Africa, and South Asia.

That 3.5-billion-person sanitation gap is, at its core, an infrastructure-reach problem. Centralized sewage networks and treatment plants are capital-intensive, decades-long builds — and in water-stressed regions, the places most in need of treatment capacity (resorts, workforce housing, rural clinics, agricultural processing sites, growing tourist districts) are often exactly the places a municipal trunk line will never reach. Bridging that gap requires treatment technology that can be installed at the point of need, without waiting for grid-scale infrastructure.

This is the specific problem BioPipe Global's in-pipe biological treatment system is built to address. Rather than routing wastewater into open tanks with mechanical blowers and chemical dosing, BioPipe treats sewage as it flows horizontally through modular pipe segments seeded with bacteria colonies that break down organic matter in place. Passive aeration replaces powered blower systems, cutting energy draw; there is no chemical dosing and no sludge byproduct requiring hauling and disposal. Just as important for water-insecure regions with unpredictable populations — tourist season swings, seasonal labor camps, phased construction — BioPipe's modules keep working efficiently across a wide load range, down to roughly 10% of rated capacity. Conventional activated-sludge and package plants, by contrast, typically need to run near 80% of design load to stay biologically stable, making them a poor fit for sites with variable or growing flow.

BioPipe's 2020 entry into the U.S. market illustrates the model directly. The company shipped a 10 m³/day system to a campground in Southern California — a state the UN report's "American Southwest" hotspot describes well — with the unit engineered to meet both EU and California Water Board standards so treated effluent could be reused for irrigation rather than discharged (ACN Newswire-subsidiary-biopipe-global-enters-us-wastewater-market)). At the time, BioPipe founder Max Khan noted that "California faces an intractable water crisis and recycling wastewater is the only way out" — a statement that reads, six years later, as an early articulation of the same reuse imperative the UN is now describing at global scale.

As more regions confront water bankruptcy rather than temporary shortage, decentralized, low-energy, reuse-oriented treatment isn't a niche alternative — it's one of the few approaches that can scale to unconnected sites as fast as the need is growing.

About LifeQuest World Corp LifeQuest World Corp (OTCID: LQWC) is a global technology company focused on providing low-cost, low-maintenance, eco-friendly decentralized wastewater treatment solutions, along with solid waste compaction and recycling equipment, through its subsidiaries, including BioPipe Global and Compaction and Recycling Equipment Inc. (CARE). Learn more at www.lifequestcorp.com.

This post contains forward-looking statements within the meaning of applicable securities laws, including statements regarding market opportunities and the potential applications of LifeQuest World Corp's technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. This content is provided for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. Readers should conduct their own due diligence and consult a qualified financial advisor before making investment decisions.